Potential carrier priming effect in Australian infants after 7-valent pneumococcal conjugate vaccine introduction

Figure 1 Flowchart showing the selection process of analysed cases and their median ages. ¹Australian non-Indigenous immunocompetent infants with receipt of first dose of 7vPCV after diphtheria, tetanus and acellular pertussis vaccine. NNDSS: National Notifiable Diseases Surveillance System; 7vPCV: 7-valent pneumococcal conjugate vaccine; VT-IPD: Vaccine type invasive pneumococcal disease; NVT-IPD: Non-vaccine type invasive pneumococcal disease.

Figure 2 Number of vaccine type invasive pneumococcal disease cases 9 wk after a single carrier primed dose of the 7-valent pneumococcal conjugate vaccine among non-Indigenous Australian infants (2001-2006). VT-IPD: Vaccine type invasive pneumococcal disease.

Figure 3 Number of vaccine type invasive pneumococcal disease compared to non-vaccine type invasive pneumococcal disease cases 9 wk after single carrier primed dose of 7-valent pneumococcal conjugate vaccine among non-Indigenous Australian infants (2001-2006). IPD: Invasive pneumococcal disease; VT: Vaccine type; NVT: Non VT.

Figure 4 Number of vaccine type invasive pneumococcal disease cases 9 wk after a single carrier primed dose of 7-valent pneumococcal conjugate vaccine compared to the vaccine type invasive pneumococcal disease cases after non-carrier primed single 7-valent pneumococcal conjugate vaccine dose among non-Indigenous Australian infants (2001-2006). IPD: Invasive pneumococcal disease; VT: Vaccine type.

Figure 5 Number of vaccine type invasive pneumococcal disease cases among non-Indigenous Australian in children aged < 2 mo (2001-2010). VT-IPD: Vaccine type invasive pneumococcal disease.